Clinical trials: Cannabidiol
Long COVID
Feasibility of Cannabidiol for the Treatment of Long COVID
This is an open label, phase 2 clinical trial to assess the feasibility of a cannabidiol (CBD) dominant medicinal cannabis for the treatment of Long COVID.
- Trial name
- NCT04997395
- Testing
- MediCabilis Cannabis sativa 50
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Bod Australia
Social Anxiety, Social Anxiety Disorder
Cannabidiol to Reduce Anxiety Reactivity
This study seeks to understand how cannabidiol (CBD) - a non-intoxicating chemical compound obtained from the Cannabis sativa plant - affects biological and stress-related responses that are believed to underlie anxiety…
- Trial name
- NCT05823753
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of California, San Diego
Epilepsy, Dravet Syndrome
GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.
- Trial name
- NCT02224703
- Testing
- GWP42003-P
- Where
- 38 sites in United States, Australia and 4 more
- Volunteers
- 199 people
- Sponsor
- Jazz Pharmaceuticals
PTSD
Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults
Post-traumatic stress disorder (PTSD) is a psychiatric disorder than may develop following a traumatic event including serious incidents, natural or human-caused disasters, violence, death of a loved one, receipt of traumatic…
- Trial name
- NCT05269459
- Testing
- Cannabidiol Administered as Nantheia ATL5
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- University of Nebraska
Arthralgia, Breast Cancer
Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias
Study of Cannabidol to examine the safety and efficacy of 15 weeks of CBD in postmenopausal women with aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
- Trial name
- NCT04754399
- Testing
- Cannabidiol (CBD)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Epilepsy
A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epilepsy
The purpose of this study is to assess the efficacy of the adjuvant use of cannabidiol administered twice daily in doses of 5-25 mg/kg/day through the proportion of responsive patients; that is, participants with at least 50%…
- Trial name
- NCT02783092
- Testing
- Cannabidiol
- Where
- Brazil
- Volunteers
- 126 people
- Sponsor
- Antonio Waldo Zuardi
Generalized Anxiety Disorder, Social Anxiety Disorder
Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study
This proposed study aims to evaluate the efficacy of daily Cannabidiol (CBD) Oil Capsules in treating symptoms of DSM-5 anxiety disorders, using a two-arm, 8-week randomized, placebo-controlled trial in adults aged 21-65 years.
- Conditions
- Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia
- Trial name
- NCT03549819
- Testing
- Cannabidiol (CBD) Oil Capsules, Sunflower Lecithin Oil in Capsule
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- McMaster University
Multiple Sclerosis
An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients
A study to compare the efficacy of GW-1000-02 [named Sativex® in Canada and also named Sativex® Oromucosal Spray] with placebo in relieving five key symptoms of Multiple Sclerosis after six weeks of therapy.
- Trial name
- NCT01610700
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- Jazz Pharmaceuticals
Glioblastoma
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Glioblastoma (GBM) is the most common malignant brain tumor among adults. As the diagnosis is generally considered terminal, patients with GBM often suffer from anxiety and other comorbid conditions, including depression, pain…
- Trial name
- NCT05753007
- Testing
- Cannabidiol (CBD)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mclean Hospital
Epilepsy
Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy
This is an observational, open-label, flexible dose study that will prospectively and longitudinally assess the effect of Cannabidiol (CBD) therapy in patients with drug-resistant epilepsies through a Physician Expanded Access…
- Trial name
- CBD (NCT02660255)
- Testing
- Cannabidiol
- Where
- United States
- Sponsor
- University of Nebraska
Urinary Stone
A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones
The purpose of this study is to determine if CBD oil has any effect on decreasing postoperative pain control following ureteroscopy for urinary stone disease, and to determine if CBD oil has any effect in decreasing the amount of…
- Trial name
- NCT04387617
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Mayo Clinic
Developmental and Epileptic Encephalopathy (DEE)
A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE
The efficacy, safety, and tolerability of CBD-OS have been evaluated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous sclerosis complex (TSC).
- Trial name
- NCT07723976
- Testing
- CBD-OS
- Volunteers
- 120 people
- Sponsor
- Jazz Pharmaceuticals
Effect of Drug
Topical Cannabidiol Application and Skin Vascular Reactivity
Cannabidiol, or CBD, is an over-the-counter "nutraceutical" that is more commonly being used by healthy adults for pain management, recovery from strenuous exercise, and general wellness.
- Trial name
- cannabidiol (NCT05456113)
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Penn State University
Social Anxiety Disorder
Cannabidiol as a Treatment for Social Anxiety Disorder (R61)
The R61 will include two CBD dose levels vs placebo (PBO) and examine potential engagement with two primary targets in a 3-week randomized controlled trial design.
- Trial name
- NCT05571592
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Refractory Epilepsy
Expanded Use of Cannabidiol Oral Solution
To allow subjects who have completed Insys 030 extension study to continue to take Cannabidiol oral solution.
- Trial name
- NCT03196934
- Testing
- Cannabidiol oral solution
- Sponsor
- MultiCare Health System Research Institute
Cannabis, Cannabis Intoxication
Do Adolescents and Adults Differ in Their Acute Response to Cannabis?
The acute effects of cannabis may differ between adolescents and adults. Furthermore, these effects may be tempered by the presence of cannabidiol.
- Conditions
- Cannabis, Cannabis Intoxication, Cannabis Use, Cannabis Dependence
- Trial name
- CannTeenA (NCT04851392)
- Testing
- Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), Cannabis with THC without CBD
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University College, London
Graft Versus Host Disease
Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation
Graft versus host disease (GVHD) is one of the major causes of death in patients undergoing allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT01596075
- Testing
- Cannabidiol
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Rabin Medical Center
Tourette Syndrome, Cannabis
The Effect of Medical Cannabis on Tics, Premonitory Urge and Psychiatric Comorbidity in Adults With Tourette Syndrome
Medical cannabis (MC) is a standard treatment in Israel to adults with resistant Gilles de la Tourette syndrome (GTS). While small randomized control trials assessed THC efficacy on tics and premonitory urge, only small…
- Trial name
- NCT05115318
- Testing
- Medical Cannabis
- Where
- Israel
- Volunteers
- 18 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
HIV Seropositivity
Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients
Autophagy and apoptosis are natural cellular mechanisms which consist for the first in a recycling and elimination process of potentially toxic cellular waste, and for the second in a process of cellular suicide when it becomes…
- Trial name
- GALIG-CBD (NCT05306249)
- Testing
- CBD LGP 50
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification
Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving
Cannabidiol (CBD), one of the most prevalent cannabinoids in cannabis (marijuana) has been shown to reduce alcohol withdrawal symptoms in laboratory animals.
- Conditions
- Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification, Craving
- Trial name
- NCT07148843
- Testing
- Cannabidiol (CBD)
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Johns Hopkins University